MCE - Delayed Quote EUR

Grifols, S.A. (GRF.MC)

8.45

+0.06

(+0.76%)

At close: 5:41 PM GMT+2

Grifols 2023 Annual Report on Form 20-F filed with the SEC

Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the United States Securities and Exchange Commission ("SEC").

PR Newswire 9 days ago

GIFLF

GIFOF

GIKLY
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.

The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The flagship Grifols campus is a touchstone of Grifols’ leadership in plasma therapeutics, producing about 40% of the company’s total medicinal output globally and helping enhance the quality of life of patients all over the worldAn engineering masterwork, the Clayton site is a model for new Grifols plants whi

GlobeNewswire 11 days ago

GIFLF

GIFOF

GIKLY
Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper

MADRID (Reuters) -Spanish drug maker Grifols, battling a plunge in its share price this year, plans to add independent directors to its audit and compensation committees to improve its governance, its chairman said in a newspaper interview published on Sunday. Grifols' market value has shed billions of euros since short-sheller Gotham City Research released three reports in early January accusing the company of overstating earnings and understating debt. Grifols has repeatedly denied the claims.

Reuters 15 days ago

GRFS
Grifols Plans First Bond Sale Since Short Seller Attack

(Bloomberg) -- Grifols SA is seeking to issue a new bond, in what would be its first debt deal since coming under attack from a short seller in January.Most Read from BloombergUS Slams Strikes on Russia Oil Refineries as Risk to Oil MarketsUS Core CPI Tops Forecasts Again, Likely Delaying Fed Rate CutsChinese Cement Maker Halted After 99% Crash in 15 MinutesBond Trader Places Record Futures Bet on Eve of Inflation DataApple’s India iPhone Output Hits $14 Billion in China ShiftThe Barcelona-based

Bloomberg 19 days ago

GRFS
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

Grifols’ in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infections Arboviruses are a growing emerging threat, with changes in climate and increasing global connectivity making the geographic spread more prevalent CE mark for Grifols’ Procleix ArboPlex Assay reinforces the company’s leadership in transfusion medicine and commitment to ensuring the safety of the world’s blood supply BARCELONA, Spain, April 04, 2024 (GLOBE NEWSWIRE

GlobeNewswire 25 days ago

GIFLF

GIFOF

GIKLY
Health Care Roundup: Market Talk

Read about Novo Nordisk, Grifols, Shandong Weigao and more in the latest Market Talks covering the Health Care sector.

The Wall Street Journal last month

GIFLF

GIFOF

GIKLY
UPDATE 2-Europe's STOXX 600 logs weekly gains, US jobs data in focus

Europe's main stock indices were flat on Friday, but notched strong gains over the week that saw record highs from German and French shares, while investors also analysed a U.S. jobs report for clues on the global monetary policy outlook. Technology lost 1.6% after BE Semiconductor slumped 16.1% on a media report that Joint Electron Device Engineering Council lowered certain chip standards which might delay investments into hybrid bonding technology.

Reuters last month

^GDAXI

^FCHI

BESIY
Spanish Healthcare Firm Grifols Hit With New Gotham City's Short Report, Faces Questions Regarding Transparency, Integrity, Ethical Conduct

Grifols SA (NASDAQ:GRFS) shares are down on Wednesday following the publication of a new report by Gotham City Research questioning the company’s “transparency, integrity and ethical conduct.” Grifols had previously denied Gotham City’s accusations, as per its February SEC filing, saying it had already replied to all of the questions raised in the latter’s reports. Grifols claimed in its public February 20 response that the company had addressed all our questions, yet new information from the Ke

Benzinga last month

GRFS
GRFS or ZTS: Which Is the Better Value Stock Right Now?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Zacks 2 months ago

ZTS

GRFS
Grifols announces positive topline phase 3 fibrinogen clinical trial results

In the AdFIrst study, Biotest's fibrinogen concentrate (FC), BT524, met the primary endpoint, demonstrating its effectiveness in treating acquired fibrinogen deficiency (AFD) as equivalent to standard of care, while maintaining an excellent safety profileRegulatory approval process in Europe and United States set to begin in Q4 2024. It would be the first FC approved for an AFD indication in the U.S. in a global market for AFD with an estimated potential of USD 800 millionThis milestone is part

GlobeNewswire 2 months ago

GIFLF

GIFOF

GIKLY
Here's Why Grifols (GRFS) Is a Great 'Buy the Bottom' Stock Now

Grifols (GRFS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks 2 months ago

GRFS
UPDATE 1-Spain's Grifols sues Gotham City fund, JV over damaging report

Spanish pharmaceutical company Grifols said on Friday it filed a lawsuit in a U.S. court against the founder of short-seller fund Gotham City Research, Daniel Yu, and his company, seeking damages over a report suggesting accounting irregularities at Grifols. The lawsuit, filed in U.S. District Court in Manhattan, also named as defendants Portsea founder Cyrus de Weck and General Industrial Partners, which is a joint venture between Yu and de Weck, and their affiliates.

Reuters 3 months ago

GRFS
Here's Why Grifols (GRFS) is Poised for a Turnaround After Losing -31.55% in 4 Weeks

Grifols (GRFS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 3 months ago

GRFS
Grifols says Haier Group still OK to buy stake in Shanghai RAAS

Spanish pharma company Grifols said on Sunday evening Chinese home appliance maker Haier Group still plans to close the acquisition of a 20% stake in Shanghai RAAS Blood Products as announced in late December. Grifols currently owns 26.58% in Shanghai RAAS. Grifols quoted Haier Group's chairwoman saying: "We continue to work to close the deal as originally planned," in a filing to the Spanish stock market regulator.

Reuters 3 months ago

GRFS

002252.SZ
Grifols shares suffer worst week on record after short-seller report

Shares in Spanish pharma firm Grifols dropped another 10% on Friday, bringing their weekly loss to nearly 40% after short-seller Gotham City Research accused the Barcelona-based business of manipulating its financial accounts. When contacted by Reuters this week, Grifols rejected Gotham's allegations, which were made in a report published on Tuesday. Grifols, which makes medicines from human blood plasma, has also said it will sue the short-seller and seek compensation.

Reuters 3 months ago

GRFS
GRFS vs. ZTS: Which Stock Is the Better Value Option?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Zacks 3 months ago

GRFS

ZTS
Grifols sees China stake sale going ahead despite Gotham City report

BARCELONA/LONDON (Reuters) -Grifols told investors on Thursday it did not foresee any problem closing its $1.8 billion sale of a stake in Shanghai RAAS, despite a slump in its shares after a Gotham City Research report this week querying the Spanish drugmaker's accounting. Shares in Grifols fell by as much as 13% in afternoon trading after the company held a conference call to reassure its investors. The company's stock has lost more than 28% of its value since the Gotham City report came out on Tuesday.

Reuters 3 months ago

GRFS
Spain's Grifols to sue short-seller over critical report, shares jump

BARCELONA (Reuters) -Spanish pharma company Grifols said on Wednesday it would launch legal action against Gotham City Research after the short-seller fund published a critical report that wiped $2.5 billion off the Barcelona-based firm's market value on Tuesday. After shedding 2% earlier on Wednesday, Grifols shares reversed to trade 7.4% higher in the early afternoon, after the firm said it would seek compensation in court for the financial and reputational damage to the company and its shareholders. Board member Tomas Daga, who sits on Grifols' audit committee and has advised it as a lawyer on several acquisitions, told Reuters the lawsuit would seek compensation at least equivalent to the share price loss.

Reuters 3 months ago

GRFS
Factbox-What does the Gotham City report say about Grifols?

Shares in Grifols fell as much as over 40% on Tuesday, wiping $3.83 billion off its market value, after hedge fund Gotham City Research questioned its accounting, prompting the Spanish drugmaker to "categorically" deny any wrongdoing. Gotham City Research said that Grifols received almost all of its earnings from so-called "non-controlling interests." These satellite companies a few of which the shortseller focused on in its report, include blood donation firm Haema AG, plasma donation company BPC Plasma and testing firm Grifols Diagnostics Solutions, account for 96.8% of the company's profits, the report says.

Reuters 3 months ago

GRFS
Factbox-What is Grifols and why have its shares slumped?

Grifols categorically denied any wrongdoing. In a regulatory filing it called the report "false information" and said it had disclosed all information with integrity and transparency. To finance its international expansion, Grifols has taken on debt, which leading credit ratings agencies rate at below investment-grade.

Reuters 3 months ago

GRFS

Performance Overview

Return	GRF.MC	IBEX 35...
YTD	-45.33%	+9.89%
1-Year	-9.33%	+20.13%
3-Year	-62.52%	+26.15%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Grifols, S.A. (GRF.MC)

Grifols 2023 Annual Report on Form 20-F filed with the SEC

Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.

Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper

Grifols Plans First Bond Sale Since Short Seller Attack

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

Health Care Roundup: Market Talk

UPDATE 2-Europe's STOXX 600 logs weekly gains, US jobs data in focus

Spanish Healthcare Firm Grifols Hit With New Gotham City's Short Report, Faces Questions Regarding Transparency, Integrity, Ethical Conduct

GRFS or ZTS: Which Is the Better Value Stock Right Now?

Grifols announces positive topline phase 3 fibrinogen clinical trial results

Here's Why Grifols (GRFS) Is a Great 'Buy the Bottom' Stock Now

UPDATE 1-Spain's Grifols sues Gotham City fund, JV over damaging report

Here's Why Grifols (GRFS) is Poised for a Turnaround After Losing -31.55% in 4 Weeks

Grifols says Haier Group still OK to buy stake in Shanghai RAAS

Grifols shares suffer worst week on record after short-seller report

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Grifols sees China stake sale going ahead despite Gotham City report

Spain's Grifols to sue short-seller over critical report, shares jump

Factbox-What does the Gotham City report say about Grifols?

Factbox-What is Grifols and why have its shares slumped?

Performance Overview